AzTrials
AzTrials

Obesity, AbdominalNCT06891534

Circadian Rhythms in Human Adipose

A study testing Continuous Feeding and Intermittent feeding in people with Obesity, Abdominal and Feeding Patterns, run by Mayo Clinic at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to understand the underlying circadian rhythms in subcutaneous adipose tissue of humans with our without continuous feeding and how these are altered in people who have obesity. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Obesity, Abdominal, Feeding Patterns
What is being tested?
Continuous Feeding and Intermittent feeding
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteUnited States
Study dates
1 Jul 2021to Dec 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • BMI 20-25 kg/m2 or 30-37 kg/m2
  • For participants with obesity a waist-to-hip ratio of ≥0.95 in males and ≥0.90 in females.
  • sedentary
  • females: non pregnant or breastfeeding
  • ability to provide written informed consent and follow study instructions

Who cannot join

  • History of mediations that impact adipocyte/lipid metabolism
  • smoking
  • insomnia
  • sleep apnea
  • sleep medication use
  • employment in night or shift work
  • extreme chronotypes
  • Allergy to lidocaine

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Kelli A Lytle, PhD contact

507-255-1488

lytle.kelli@mayo.edu

United States1 site, 1 recruiting
  • Mayo Clinic

    Rochester, Minnesota, 55901

    Kelli A Lytle, PhD, 503-255-1488, lytle.kelli@mayo.edu

    Recruiting

Other trials in United States

About this study

Official title: Circadian Regulation of Human Adipose Tissue Metabolism

The goal of this study is to understand the underlying circadian rhythms in subcutaneous adipose tissue of humans with our without continuous feeding and how these are altered in people who have obesity.

Read the detailed description

This proposal will address 3 main aims: 1) Determine the impact of endogenous AT circadian rhythms on AT function independent of diurnal nutrient delivery in humans, 2) determine the impact of central obesity on adipocyte circadian clock, and 3) establish for the first-time in vivo human adipocyte specific cistrome of the core circadian clock transcription factors, BMAL1 and CLOCK. In order to understand whether adipocytes have intrinsic circadian clock entrainment that is separate from food entrainment, we will compare rhythmicity of AT of lean volunteers studied under continuous vs. intermittent feeding paradigms. 20 normal weight adults (M/F= 10/10, split evenly between feeding groups) will be randomized to receive either "continuous" (CONT) feedings via a nasogastric (NG) feeding tube or receive 3 meals a day for the "intermittent" (INTER) study, also delivered via NG tube. The screening prior to the inpatient study visit will include vital signs, height, weight, hip/waist/neck circumference, body composition (DEXA scan) plasma lipid profile and fasting glucose. Potential volunteers will fill out questionnaires to exclude sleep disorders and assure normal sleep habits. For 3 days prior to and during the inpatient study, volunteers will be required to wear an Actiwatch 24 h/day; which objectively measures 24-hour sleep quality and quantity. (see detailed methodology).

For the inpatient visit, volunteers will be admitted to Mayo Clinic Clinical Research and Trials Unit (CRTU) at 1500 h where an NG tube will be placed. After baseline blood samples, the CONT feeding group will start liquid feedings (Ensure Plus®) at 1800 and continue for the next ~37 hrs. This will provide 12 h of continuous feeding before the first abdominal AT biopsies; this duration of continuous feeding abolishes the wide fluctuations in plasma insulin that occurs with normal meals and will avoid the progressive lipolytic response that would occur if fasting were used as the experimental design. FFA during isocaloric, continuous feeding is well within normal intraday variability. Participants randomized to INTER will receive 1/3rd of their daily energy needs at each "meal" via NG tube. These feedings will be given at 1800 h and 3 separate meals the following day. Participants will undergo measures of resting energy expenditure following the overnight period to appropriately interpret FFA Ra data.

To avoid retrieving AT sample from previously disrupted biopsy sites, every participant will be limited to 4 abdominal adipose tissue biopsies (1 per abdominal quadrant). To ensure a full 24 hours of data, all participants will have biopsies at: 0600, 1800, and 0600 the next day, half of participants will have a biopsy at 1200 and the other half at 2400. This hybrid (linked-cross sectional) will allow us to sample in series from multiple people and then create sample group means to account for disparate biopsy numbers. We are sampling from abdominal adipose tissue as this is the primary source of circulating FFA in humans and thus is the most likely for us to ascertain regulation of lipolysis proteins.

Being tested
Continuous Feeding, Intermittent feeding
Keywords
circadian rhythms, adipose tissue, obesity, feeding pattern
Medical subject headings
Obesity, Abdominal, Feeding Behavior, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous FeedingOther

    Participants will receive 24-hour continuous feeds through an NG tube

  • Intermittent feedingOther

    Participants will receive 3 boluses of feeding per day at regular meal times through an NG tube to mimic normal meals.

Study groups in NCT06891534
Study groupRoleWhat they receive
Normal weight participantsActive comparatorNot described
Receives: Other: Continuous Feeding; Other: Intermittent feeding
Participants with obesityActive comparatorNot described
Receives: Other: Continuous Feeding; Other: Intermittent feeding

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. rhythmicity of circadian clock mRNA in adipose tissue

    Genes from RNA-seq analysis will be defined as statistically rhythmic.

    Measured: 24 hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2025
  2. Study start1 Jul 2021
  3. Primary completionDec 2029 (estimated)
  4. Study completionDec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06891534
Sponsor's protocol ID
20-004280
Other IDs
K01DK140206
Status last verified
Apr 2026
First submitted
17 Mar 2025
Last updated
14 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Continuous Feeding and Intermittent feeding in people with Obesity, Abdominal and Feeding Patterns, run by Mayo Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kelli A Lytle, PhD (507-255-1488, lytle.kelli@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

rhythmicity of circadian clock mRNA in adipose tissue (time frame: 24 hour). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in